[Form 4] Zymeworks Inc. Insider Trading Activity
Rhea-AI Filing Summary
Zymeworks Inc. Chief Scientific Officer Paul Andrew Moore reported multiple equity transactions on January 12, 2026. One third of a prior restricted stock unit (RSU) grant vested, resulting in 17,666 shares of common stock, and 9,560 shares were sold at a weighted average price of $22.6735 solely to cover tax withholding and related fees under a mandatory sell-to-cover provision. After these transactions, he directly held 48,497 shares of common stock.
On the same date, Moore received new equity awards, including 70,000 stock options with a $23.16 exercise price that vest 25% after one year and the rest in 36 monthly installments. He was also granted 47,000 RSUs vesting in four equal annual installments and 66,000 performance stock units, representing the maximum shares that may be earned based on total shareholder return goals over a three-year period ending January 12, 2029, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 17,666 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 70,000 | $0.00 | -- |
| Grant/Award | Restricted Stock Unit | 47,000 | $0.00 | -- |
| Grant/Award | Performance Stock Unit | 66,000 | $0.00 | -- |
| Exercise | Common Stock | 17,666 | $0.00 | -- |
| Sale | Common Stock | 9,560 | $22.6735 | $217K |
Footnotes (1)
- Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 10, 2025. Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date. Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. RSUs vest in four equal annual installments beginning on first anniversary of grant date. Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 33,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, (Continued from footnote 8) except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control).
